CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

Core Insights - CollPlant Biotechnologies announced positive results from a comparative study of its rhCollagen-based bioink, Collink.3D™, which outperformed Matrigel® in supporting structured tissue formation [1][8]. Company Overview - CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, utilizing proprietary plant-based genetic engineering technology to produce rhCollagen [9]. Product Details - Collink.3D™ is a recombinant human type I collagen methacrylamide bioink, produced without animal-derived substances, designed to mimic the native properties of human tissues and organs [6][7]. - The bioink enables scalable and reproducible biofabrication of 3D tissue and organ models, supporting drug screening and therapeutic research [7]. Study Findings - The study conducted by the Levenberg Lab at Technion demonstrated that Collink.3D™ exhibited enhanced mechanical strength, elasticity, and stability compared to Matrigel®, suggesting it may serve as a next-generation, animal-free extracellular matrix [3][5]. Market Insights - The global market for basement membrane matrices, including Matrigel and similar products, was valued at approximately $96 million in 2024 and is projected to reach $201 million by 2031, growing at a CAGR of 11.2% [4].